Venrock Adviser, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001615982

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q4 2025 · 27 positions · Total reported value $2.02B · Top-10 concentration 73.7% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 41.0% · 6 new · 5 cut · 5 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q4 2025 13F filing, Venrock Adviser, LLC disclosed 27 equity positions with a combined reported value of $2.02B. The filing implies a focused portfolio: its ten largest positions account for 73.7% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were APGE ($641.08M), ORKA ($125.74M), VRDN ($120.83M). By sector, the heaviest allocations are Health Care 62.9%, Materials 0.0%. Versus the prior quarter, allocation shifted toward Health Care (+4.2pp) and away from Other (-4.2pp).

Versus the prior quarter, Venrock Adviser, LLC opened 6 new positions, trimmed 5 and fully exited 5, a turnover rate of 41.0% of positions. The portfolio's overlap with the prior quarter was 76% of names.

The largest new positions opened in Q4 2025 were HELP ($31.41M).

Of the 5 positions fully exited versus the prior quarter, the largest were MTSR ($196.27M), CDTX ($90.66M), ABVX ($48.96M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • HELP CYBIN INC · $31.41M

Fully Exited (vs previous quarter)

  • MTSR METSERA INC · prev qtr: $196.27M
  • CDTX CIDARA THERAPEUTICS INC COM NEW · prev qtr: $90.66M
  • ABVX ABIVAX SA · prev qtr: $48.96M
  • ATXS ASTRIA THERAPEUTICS INC · prev qtr: $17.89M
  • PHVS PHARVARIS N V · prev qtr: $16.83M
  • PCSC PERCEPTIVE CAP SOLUTIONS COR · prev qtr: $7.95M
  • TENX TENAX THERAPEUTICS INC · prev qtr: $3.33M

Insider Transactions (Form 4)

Latest Venrock Adviser, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Venrock Adviser, LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 34 US equity positions with a combined value of $2.06B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-79382 (status: Approved), registered 2014-04-09
  • Regulatory AUM (Form ADV): $4.50B as of 2026-04-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 7 private funds, of which 1 hedge funds

Portfolio Structure

  • 34 positions · $2.06B reported value (Q3 2026)
  • Top 10 holdings = 71.0% of reported value
  • Largest position: ORKA (ORUKA THERAPEUTICS INC) at 16.8%
  • Average position size: $60.54M

Sector Tilt

  • Health Care 99.6%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 6 new, 6 added, 5 reduced, 5 exited
  • 17 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 62.9%
Materials 0.0%
Other 37.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 8.49M $641.08M 31.67%
31.67%
Hold
2 4.15M $125.74M 6.21%
6.21%
Hold
3 3.88M $120.83M 5.97%
5.97%
Hold
4 3.69M $120.74M 5.96%
5.96%
Add
5 6.73M $108.67M 5.37%
5.37%
Hold
6 7.32M $88.81M 4.39%
4.39%
Reduce
7 13.74M $82.85M 4.09%
4.09%
Add
8 2.00M $71.04M 3.51%
3.51%
Reduce
9 17.86M $66.43M 3.28%
3.28%
Hold
10 15.56M $66.29M 3.27%
3.27%
Hold
11 1.55M $64.16M 3.17%
3.17%
Add
12 3.22M $49.69M 2.45%
2.45%
Hold
13 3.23M $49.69M 2.45%
2.45%
Hold
14 5.68M $46.43M 2.29%
2.29%
Reduce
15 4.77M $43.09M 2.13%
2.13%
Reduce
16 2.17M $42.52M 2.10%
2.10%
Hold
17 1.00M $41.21M 2.04%
2.04%
Add
18 1.17M $31.75M 1.57%
1.57%
Hold
19 3.84M $31.41M 1.55%
1.55%
New
20 5.35M $28.01M 1.38%
1.38%
Add
21 1.94M $25.42M 1.26%
1.26%
Add
22 2.13M $25.30M 1.25%
1.25%
Add
23 610.81K $17.03M 0.84%
0.84%
Hold
24 632.93K $14.30M 0.71%
0.71%
Hold
25 1.38M $14.28M 0.70%
0.70%
Hold
26 1.61M $6.91M 0.34%
0.34%
Hold
27 987.26K $839.17K 0.04%
0.04%
Hold

FAQ

What did Venrock Adviser, LLC buy in 2025-Q4?

In its 2025-Q4 13F filing, Venrock Adviser, LLC reported 27 equity positions worth $2.02B in aggregate; its largest disclosed positions were APGE ($641.08M), ORKA ($125.74M), VRDN ($120.83M).

How large is Venrock Adviser, LLC's portfolio?

Venrock Adviser, LLC reported $2.02B of long equity holdings across 27 positions as of 2025-Q4. Top-10 holdings account for 73.7% of reported value.

What is Venrock Adviser, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/venrock-adviser/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →